Dupilumab subgroup responder analysis: a post hoc analysis from LIBERTY PRIME and PRIME2 in prurigo nodularis

Key Points

• This analysis aims to evaluate the efficacy of dupilumab in treating prurigo nodularis across different subgroups.
• Conducted a post hoc analysis of data from LIBERTY PRIME and PRIME2 trials.
• Examined effects of dupilumab relative to age, gender, comorbidities, and prior medication.
• Evaluated responder rates in various demographic and clinical subgroups.
• Dupilumab showed positive effects independent of age and gender.
• Efficacy was consistent across individuals with different comorbidities.
• Prior medication use did not significantly influence dupilumab's effectiveness.

Abstract